Industry
Biotechnology
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Loading...
Open
10.32
Mkt cap
259M
Volume
538K
High
10.47
P/E Ratio
-38.54
52-wk high
11.11
Low
8.43
Div yield
N/A
52-wk low
3.03
Portfolio Pulse from Benzinga Newsdesk
October 03, 2024 | 10:35 am
Portfolio Pulse from Benzinga Newsdesk
September 04, 2024 | 10:55 am
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 9:12 pm
Portfolio Pulse from Benzinga Newsdesk
July 15, 2024 | 8:08 pm
Portfolio Pulse from Benzinga Newsdesk
July 15, 2024 | 8:07 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 9:05 pm
Portfolio Pulse from Benzinga Newsdesk
May 06, 2024 | 4:40 pm
Portfolio Pulse from Benzinga Newsdesk
April 30, 2024 | 11:01 am
Portfolio Pulse from Benzinga Newsdesk
April 18, 2024 | 8:29 pm
Portfolio Pulse from Benzinga Insights
March 22, 2024 | 1:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.